SEARCH:   Advanced

Blood, 1 April 2006, Vol. 107, No. 7, pp. 2639-2642. Prepublished online as a Blood First Edition Paper on December 13, 2005; DOI 10.1182/blood-2005-08-3518. This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 2005-08-3518v1 107/7/2639    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bennett, C. M. Articles by Neufeld, E. J. Search for Related Content PubMed PubMed Citation Articles by Bennett, C. M. Articles by Neufeld, E. J. Related Collections Hemostasis, Thrombosis, and Vascular Biology Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief report Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura Carolyn M. Bennett, Zora R. Rogers, Daniel D. Kinnamon, James B. Bussel, Donald H. Mahoney, Thomas C. Abshire, Hadi Sawaf, Theodore B. Moore, Mignon L. Loh, Bertil E. Glader, Maggie C. McCarthy, Brigitta U. Mueller, Thomas A. Olson, Adonis N. Lorenzana, William C. Mentzer, George R. Buchanan, Henry A. Feldman, Ellis J. Neufeld, the Pediatric Rituximab/ITP Study Group and the Glaser Pediatric Research Network From the Division of Hematology/Oncology and the Clinical Research Program, Children's Hospital Boston, Dana-Farber Cancer Institute and Harvard Medical School, MA; the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas; Weill Medical College at Cornell University, New York, NY; Baylor College of Medicine, Houston, TX; Emory University School of Medicine, Atlanta, GA; Van Eslander Cancer Center, St John Hospital, Detroit, MI; University of California, Los Angeles (UCLA)/Mattel Children's Hospital at UCLA; University of California, San Francisco; and Stanford University, CA. We assessed safety and efficacy of rituximab in a prospective study of 36 patients, age 2.6 to 18.3 years, with severe chronic immune thrombocytopenic purpura (ITP). The primary outcome of sustained platelets above 50 x 109/L (50 000/mm3) during 4 consecutive weeks, starting in weeks 9 to 12, was achieved by 11 of 36 patients (31%, confidence interval [CI], 16% to 48%). Median response time was 1 week (range, 1 to 7 weeks). Attainment of the primary outcome was not associated with age, prior pharmacologic responses, prior splenectomy, ITP duration, screening platelet count, refractoriness, or IgM reduction. First-dose, infusion-related toxicity was common (47%) despite premedication. Significant drug-related toxicities included third-dose hypotension (n = 1) and serum sickness (n = 2). Peripheral B cells were depleted in all subjects. IgM decreased 3.4% per week, but IgG did not significantly decrease. Rituximab was well tolerated, with manageable infusion-related side effects, but 6% of subjects developed serum sickness. Rituximab is beneficial for some pediatric patients with severe, chronic ITP. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Putting the "Tux" on ITP Douglas B. Cines Blood 2006 107: 2590-2591. [Full Text] [PDF] This article has been cited by other articles: S. Berentsen Rituximab for the treatment of autoimmune cytopenias Haematologica, December 1, 2007; 92(12): 1589 - 1596. [Full Text] [PDF] B. Bader-Meunier, N. Aladjidi, F. Bellmann, F. Monpoux, B. Nelken, A. Robert, C. Armari-Alla, C. Picard, F. Ledeist, M. Munzer, et al. Rituximab therapy for childhood Evans syndrome Haematologica, December 1, 2007; 92(12): 1691 - 1694. [Abstract] [Full Text] [PDF] C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation Blood, October 15, 2006; 108(8): 2874 - 2880. [Abstract] [Full Text] [PDF] D. J. Nugent Immune Thrombocytopenic Purpura of Childhood Hematology, January 1, 2006; 2006(1): 97 - 103. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020